National Research (NRCIA) versus BTG (BTGGF) Financial Survey
National Research (OTCMKTS: BTGGF) and BTG (OTCMKTS:BTGGF) are both business services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.
Volatility and Risk
National Research has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500. Comparatively, BTG has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500.
This table compares National Research and BTG’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
National Research pays an annual dividend of $0.40 per share and has a dividend yield of 1.2%. BTG does not pay a dividend. National Research pays out 69.0% of its earnings in the form of a dividend.
This is a breakdown of recent ratings and target prices for National Research and BTG, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Earnings & Valuation
This table compares National Research and BTG’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|National Research||$117.56 million||6.99||$22.94 million||$0.58||57.84|
National Research has higher revenue and earnings than BTG.
Institutional & Insider Ownership
33.6% of National Research shares are owned by institutional investors. 5.7% of National Research shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
National Research beats BTG on 8 of the 9 factors compared between the two stocks.
About National Research
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provide actionable information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience, satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The company offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. It also provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. The company offers transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, increase patient satisfaction and support safe care transitions; and risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs. It provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems and post-acute providers, such as home health, long term care, hospice, and payer organizations. The company was founded in 1981 and is headquartered in Lincoln, Nebraska.
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of crotalid snake envenomations; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup; and Lemtrada. The company also manufactures and commercializes therapeutic ultrasound devices, and roxwood systems, as well as develops venous thrombus management devices. The company was formerly known as British Technology Group International plc and changed its name to BTG plc in March 1995. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.
Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.